Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

NCT06415773 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

367

Enrollment

INDUSTRY

Sponsor class

Conditions

T2DM (Type 2 Diabetes Mellitus)

Interventions

DRUG: HTD1801
DRUG: Dapagliflozin

Sponsor

HighTide Biopharma Pty Ltd

Collaborators

[object Object]